Regeneron Pharmaceuticals Inc. in Tarrytown, New York, recently announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined its Board of Directors.
“Today”™s announcement demonstrates our strong commitment to strategic refreshment of the board, a focus on the recruitment of new directors to complement the overall mix of skills, experience and perspectives, and further enhancement of the board”™s diversity,” said Christine Poon, lead independent director of Regeneron”™s Board.
Guarini, who will serve as an independent director, recently retired as chief information officer of IBM. Prior to that, which began in 2021, Guarini served in multiple executive leadership roles at IBM over more than 20 years. She has been included on the Top 100 Leader list (No.2 in 2022) from Technology magazine and Forbes”™ CIO Next list (2022), and she is a member of the United States Patent & Trademark Office”™s National Council for Expanding American Innovation. She earned her Bachelor of Science degree and Ph.D. in applied physics from Yale University and Stanford University, respectively.
Schenkein is a general partner and co-lead of the Life Sciences team at GV (Google Ventures). Prior to joining GV in 2019, he served as CEO for Agios Pharmaceuticals Inc. for 10 years. He previously served in clinical leadership roles at major biotechnology companies. Since 2009, Schenkein has also served as adjunct clinical professor of medicine, hematology/oncology at Tufts Medical Center. He is currently a board member of Prime Medicine Inc., Denali Therapeutics Inc., and Agios. He earned his M.D. at the State University of New York Upstate Medical School in Syracuse and completed his medical training at the Tufts University School of Medicine.
“We welcome Kathryn and David to Regeneron”™s Board, knowing they will be fantastic additions as we continue to focus on using the power of science to transform patient lives and drive shareholder value,” said Leonard S. Schleifer, M.D., Ph.D., board co-chair, president and CEO, and George D. Yancopoulos, M.D., Ph.D., board co-chair, president and chief scientific officer of Regeneron.
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, it has repeatedly and consistently translated science into medicine, which has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron”™s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.
